Human Choroid Plexus Epithelial Cell Generation via BMP4 Differentiation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods are unable to generate large numbers of human choroid plexus epithelial cells (CPECs) in culture, limiting their clinical applications, particularly for neurodegenerative diseases like Alzheimer's, due to their low proliferative nature and lack of a human source for transplantable CPECs.

Innovation Solution

The method involves differentiating human embryonic stem cells into choroid plexus epithelial cells using Bone Morphogenetic Protein 4 (BMP4) and other TGF-beta superfamily members, allowing for the generation of induced CPECs in large numbers through aggregation-based, neural rosette, and combined aggregate-monolayer methods.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Quantity of substance

If human choroid plexus epithelial cells are cultured from endogenous sources, then cell purity is maintained, but the number of cells that can be generated is limited due to low proliferative capacity

Engineering Contradiction:

Improvenumber of CPECs generatedVSAvoidcell expansion capacity

Core Design Contradiction:

Quantity of substanceVSProductivity

Solution Approach 1:

The patent uses stem cells as a copy source to generate CPECs. Instead of relying on the limited endogenous CPEC population, the invention creates copies of CPECs from pluripotent stem cells that can be expanded indefinitely, thus resolving the contradiction between maintaining cell purity and generating large numbers of cells.

Inventive Principle:

Principle #26Copying

Solution Approach 2:

The patent performs preliminary differentiation of stem cells into CPECs in a controlled laboratory setting before clinical application. This preliminary action allows for large-scale generation of cells with guaranteed purity and identity, overcoming the limitations of in vivo cell expansion.

Inventive Principle:

Principle #10Preliminary action

2Reliability

If whole choroid plexus is used as transplant source in animal models, then functional integrity is maintained, but a human source for transplantable cells is not available

Engineering Contradiction:

Improvefunctional integrityVSAvoidhuman transplant applicability

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent creates human CPECs by copying the differentiation pathway from stem cells, enabling human-specific transplant applications. This approach maintains functional integrity through controlled differentiation while achieving human adaptability that animal models cannot provide.

Inventive Principle:

Principle #26Copying

Solution Approach 2:

The patent changes the source parameter from animal choroid plexus to human stem cells, enabling human-specific applications. By controlling the differentiation parameters of stem cells, the invention achieves both functional integrity and human adaptability simultaneously.

Inventive Principle:

Principle #35Parameter changes

3Quantity of substance

If CPECs are generated from stem cells, then large numbers of cells can be produced, but the cells must be induced through complex differentiation protocols

Engineering Contradiction:

Improvenumber of CPECs generatedVSAvoiddifferentiation protocol complexity

Core Design Contradiction:

Quantity of substanceVSDevice complexity

Solution Approach 1:

The patent segments the differentiation process into distinct stages: stem cell expansion, neural differentiation, and CPEC-specific differentiation. This segmentation allows for optimization of each stage independently, managing overall complexity while achieving high cell numbers.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent uses intermediate cell types and differentiation factors as mediators to guide stem cells through the transformation into CPECs. These intermediaries simplify the overall process by breaking down the complex differentiation into manageable steps with defined markers and conditions.

Inventive Principle:

Principle #24Intermediary (Mediator)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach enables the production of large numbers of induced CPECs, which can be used for therapeutic applications, genetic engineering, and drug screening, demonstrating successful differentiation and integration into the endogenous choroid plexus, thereby addressing the limitations of previous methods.

Implementation Method 1

differentiating human embryonic stem cells into choroid plexus epithelial cells using Bone Morphogenetic Protein 4 (BMP4) and other TGF-beta superfamily members

Methodology Applied

Scientific EffectBone Morphogenetic Protein signaling:

Implementation Method 2

differentiating human embryonic stem cells into choroid plexus epithelial cells using Bone Morphogenetic Protein 4 (BMP4) and other TGF-beta superfamily members

Methodology Applied

Scientific EffectTGF-beta superfamily signaling:

Data Source

PatentUS8748176B2Generation of choroid plexus epithelial cells from human embryonic stem cells

Publication Date: 2014.06.10 RGT UNIV OF CALIFORNIA

AI summary

Choroid plexus epithelial cells are generated in a culture medium using embryonic stem cells and adding an effective amount of bone morphogenetic protein and/or other members of the transforming growth factor beta (TGF-beta) superfamily. Generation of such choroid plexus epithelial cells are confirmed using a combination of genetic markers, antibodies, histology inspection, functional assays, and integration into the endogenous choroid plexus in mice.